Shares of Dragonfly Energy (DFLI) surged 12.4% to $1.95 Monday morning after the micro-cap battery maker announced the European Patent Office allowed its application covering dry electrode manufacturing — a solvent-free process for building battery cells that cuts energy use and factory complexity. The pop comes atop a broader risk-on session, but the real question is whether patent wins can bridge the chasm between intellectual property and commercial viability for a company burning cash at an alarming rate.
• A Second Major Patent Win in Two Months, But Revenue Isn't Following
The European allowance covers "Systems and Methods for Dry Powder Coating Layers of an Electrochemical Cell."
In April, Dragonfly secured its first Japanese patent for related solid-state battery materials. The IP portfolio is growing across three continents — yet management guided Q1 2026 net sales at just ~$9.5 million , and full-year 2025 revenue was $58.6 million with a net loss of $70.3 million. Patents protect ideas; they don't generate revenue on their own.
• The Cash Runway Problem Looms Large
The company has less than a year of cash runway based on its current free cash flow, with free cash flow at negative $32 million. To fund operations, Dragonfly launched a $50 million at-the-market stock offering program in January — meaning it can sell new shares into the open market at any time, which may bolster liquidity but dilute existing shareholders over time. At a market cap around $22 million, that shelf is more than twice the company's entire value.
• Tesla Already Scaled the Same Technology
Tesla has confirmed it scaled dry electrode manufacturing and is producing battery cells using this solvent-free method.
Tesla's data shows the approach slashes equipment costs and energy consumption by roughly 90%.
Dragonfly's platform is designed to support multiple battery chemistries and advance solid-state cells , but competing against a trillion-dollar company with a head start on factory-scale production is a fundamentally different challenge than filing patents.
• Analysts See Upside — If the Company Survives
Analysts have sharply reset expectations, cutting price targets from $22.50 to as low as $3.25 , though some have reaffirmed an $18.75 target.
Short interest stands at 1.6 million shares, up 25.2% from the prior period, representing 12.3% of the float — a sign that skeptics are betting against the stock even as the patent news lands. Today's pop is encouraging, but for a company losing more money than it earns, the European patent is a brick, not a building.